December 16 2025, News Release: Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide

🚨 Arch Biopartners announced that St. Michael’s Hospital @unityhealthto.bsky.social received ethics approval to join the Phase II CS-AKI trial evaluating LSALT peptide.

🏥 4th Canadian site, 9th globally.

🔗 Read more (and share): www.archbiopartners.com/arch-biopart...

#LSALTpeptide #AKI #CSAKI

Hemolysis Index and Cardiopulmonary Bypass Time as Predictors of Cardiac Surgery-associated Acute Kidney Injury: An Observational Cohort Study Acute kidney injury (AKI) is a common and serious complication of cardiac surgery, often linked to the use and duration of cardiopulmonary bypass (CPB). The Hemolysis Index (HI) has been proposed as a...

📚 Nov 2025 study in JCVA jcvaonline.com/article/S1053-0770(25)00632-9/fulltext In >1,000 cardiac surgery patients, elevated hemolysis index, and longer bypass time predicted AKI. Supports inflammation-targeted CS-AKI therapies.

🔬 archbiopartners.com/our-science/lsaltpeptide/

#CSAKI #LSALTpeptide

Frontiers | Clinical characteristics and risk factors of cardiac surgery associated-acute kidney injury progressed to chronic kidney disease in adults: A retrospective, observational cohort study IntroductionTo retrospectively investigate the clinical characteristics and risk factors of cardiac surgery associated-acute kidney injury (CS-AKI) progresse...

📚 @frontiersin.bsky.social Cardiovasc. Med. (doi.org/10.3389/fcvm.2023.1108538) - 1 in 5 adults with CS-AKI develop CKD within 90 days.

Arch is a therapeutic biotech company supporting two Phase II AKI trials and a CKD platform.

🔬 archbiopartners.com/our-science

#CKD #CSAKI #LSALTpeptide #NephSky

Frontiers | Clinical practice guidelines for acute kidney injury: a systematic review of the methodological quality ObjectiveHospitalized patients, particularly those in the ICU, face a significant risk of acute kidney injury (AKI). Clinical practice guidelines (CPGs) that...

📚 A 2025 review confirms KDIGO 2012 as the leading AKI guideline (doi.org/10.3389/fmed.2025.1567359).

Arch Biopartners’ Phase II trial for CS‑AKI uses KDIGO to define AKI after cardiac surgery.

🔬 archbiopartners.com/our-science/metablok

#AKI #CSAKI #NephSky #ArchScience #LSALTpeptide

News release headline, clinical trial update from Arch Biopartners, August 6, 2025. Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury

Arch Biopartners’ CS-AKI Phase II clinical trial is now active at Toronto General Hospital, ranked Canada's #1 and #3 globally.

First patient dosed in the trial at this leading cardiac research hospital.

🔗 dub.sh/first-patien...

#ArchBiopartners #CSAKI #AKI #LSALTpeptide #clinicaltrials #ArchNews

Arch Biopartners Company Logo, and stock tickers (ARCH: TSX.V, and ACHFF: OTCQB). Headline, July 22, 2025 Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)

🚨 Arch Biopartners now has two lead drug candidates in active Phase II trials:

🔹 Cilastatin: in the PONTIAK trial for drug-toxin-related AKI, now open for recruitment
🔹 LSALT peptide: cardiac surgery-associated AKI

🔗 archbiopartners.com/investor-hub...

#AKI #Cilastatin #LSALTpeptide #ArchNews

Validate User

📊 Even mild post-surgical AKI raises mortality, ICU time, and costs (NDT, 2008, academic.oup.com/ndt/article-...).

🔗 Arch is targeting CS-AKI in an ongoing, sponsor-led international Phase II trial: archbiopartners.com/our-science/metablok/#trial-history

#AKI #CSAKI #KidneyCare #LSALTpeptide

Our Publications – Arch Biopartners

📘 2024 BMJ Open study (doi.org/10.1136/bmjopen-2023-076142) co-authored by Arch scientists confirmed LSALT was safe in COVID-19 patients and validated DPEP1 as a therapeutic target—key findings for the CS-AKI trial.
📖 archbiopartners.com/our-science/our-publications/
#LSALTpeptide #DPEP1 #KidneyCare

Redirecting

🧬 Weekly series for new followers—2019 Cell paper (doi.org/10.1016/j.cell.2019.07.017), co-authored by Arch scientists, identified DPEP1 as a driver of neutrophil inflammation in the kidneys, liver, and lungs.
📖 Arch Publications: dub.sh/cell-dpep1-2019
#DPEP1 #ArchScience #LSALTpeptide #KidneyCare

Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI) – Arch Biopartn...

🚨 (22 April 2025) Arch Biopartners announced that UHN-TGH (Toronto General Hospital) is prepared to begin recruiting subjects for the Phase II trial of LSALT peptide for CS-AKI.

📖 Full release at – dub.sh/arch-uhn-tgh...

#AKI #CSAKI #KidneyCare #LSALTpeptide #ArchBiopartners #DPEP1 #ArchNews

🧬 2025 JCI Insight study from Vanderbilt used LSALT peptide to reduce neutrophil binding to colorectal cancer (CRC) cells, highlighting DPEP1’s immune role.

Authors suggest LSALT could pair with ICI (immune checkpoint inhibitors) as a potential therapeutic.

#ArchBiopartners #DPEP1 #LSALTpeptide

Our Science – Arch Biopartners

Arch Biopartners is advancing two lead drug candidates:

🧪 LSALT peptide: targets inflammation-related AKI
🔬 Cilastatin: repurposed to prevent toxin-related AKI

Learn more: archbiopartners.com/our-science

#ArchBiopartners #AKI #LSALTpeptide #Cilastatin #ArchScience